KR20110033644A - Composition for curing hangover and method manufacturing thereof - Google Patents
Composition for curing hangover and method manufacturing thereof Download PDFInfo
- Publication number
- KR20110033644A KR20110033644A KR1020090091211A KR20090091211A KR20110033644A KR 20110033644 A KR20110033644 A KR 20110033644A KR 1020090091211 A KR1020090091211 A KR 1020090091211A KR 20090091211 A KR20090091211 A KR 20090091211A KR 20110033644 A KR20110033644 A KR 20110033644A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- composition
- extract
- hangover
- alcohol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 206010019133 Hangover Diseases 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 239000000284 extract Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 4
- 229930006000 Sucrose Natural products 0.000 claims abstract description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- 239000008121 dextrose Substances 0.000 claims abstract description 4
- 239000008101 lactose Substances 0.000 claims abstract description 4
- 238000012856 packing Methods 0.000 claims abstract description 4
- 239000008107 starch Substances 0.000 claims abstract description 4
- 235000019698 starch Nutrition 0.000 claims abstract description 4
- 239000005720 sucrose Substances 0.000 claims abstract description 4
- 239000011782 vitamin Substances 0.000 claims abstract description 4
- 229940088594 vitamin Drugs 0.000 claims abstract description 4
- 229930003231 vitamin Natural products 0.000 claims abstract description 4
- 235000013343 vitamin Nutrition 0.000 claims abstract description 4
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 241000132536 Cirsium Species 0.000 claims description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 13
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 13
- 229940010454 licorice Drugs 0.000 claims description 13
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 12
- 240000006891 Artemisia vulgaris Species 0.000 claims description 12
- 235000014443 Pyrus communis Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 5
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 4
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 4
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 4
- 239000001138 artemisia absinthium Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 240000005979 Hordeum vulgare Species 0.000 claims description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 2
- 239000012856 weighed raw material Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 229940069445 licorice extract Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 238000000354 decomposition reaction Methods 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 3
- 208000007882 Gastritis Diseases 0.000 abstract description 2
- 240000004510 Agastache rugosa Species 0.000 abstract 1
- 235000010686 Agastache rugosa Nutrition 0.000 abstract 1
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 1
- 241000092668 Artemisia capillaris Species 0.000 abstract 1
- 241000729173 Cirsium japonicum Species 0.000 abstract 1
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract 1
- 244000010000 Hovenia dulcis Species 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 241000037813 Polygonatum falcatum Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 49
- 239000000306 component Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 240000004670 Glycyrrhiza echinata Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 244000241838 Lycium barbarum Species 0.000 description 3
- 235000015459 Lycium barbarum Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 244000126002 Ziziphus vulgaris Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- NULAJYZBOLVQPQ-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1 NULAJYZBOLVQPQ-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- BPHHNXJPFPEJOF-UHFFFAOYSA-J chembl296966 Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3OC)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)O)OC)=CC=C21 BPHHNXJPFPEJOF-UHFFFAOYSA-J 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 244000019194 Sorbus aucuparia Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000954 inflammatory inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000006414 serbal de cazadores Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Abstract
Description
본 발명은 혈중 알코올 분해 속도를 촉진시키는 숙취 해소용 조성물 및 그의 제조방법에 관한 것으로, 보다 상세하게는 적절한 배합비율로 배합한 식물들의 추출물로 이루어진 조성물로, 알코올 섭취 후 혈중 알코올의 분해속도를 증가시키고, 항산화 활성 및 염증 억제에 의한 숙취를 해소하는 숙취 해소용 조성물에 관한 것이다.The present invention relates to a hangover-relieving composition for promoting the rate of alcohol degradation in blood and a method for manufacturing the same, and more particularly to a composition consisting of extracts of plants formulated in an appropriate blending ratio, increasing the rate of decomposition of blood alcohol after alcohol intake The present invention relates to a hangover composition for eliminating hangover caused by antioxidant activity and inhibition of inflammation.
숙취의 주요 원인은 다음의 세 가지이다.There are three main causes of hangovers:
첫째, 알코올의 작용으로 인해 술을 마시면 소변이나 땀, 기타 분비물로 많은 수분을 소비하게 된다. 그러다 보니 몸에 수분에 부족해 몸이 나른해 진다. 술 마신 뒤 갈증이 나는 것도 이 때문이다.First, because of alcohol, drinking alcohol consumes a lot of water in urine, sweat, and other secretions. As a result, the body lacks water and becomes drowsy. This is why thirsty after drinking.
둘째, 수분과 함께 미네랄과 같은 여러 가지 전해질이 몸 밖으로 배출된다. 숙취의 대표적인 증상인 몽롱하고 무기력한 증상은 바로 전해질 부족 때문에 생기는 것이다.Second, along with moisture, various electrolytes such as minerals are released out of the body. The hazy and lethargic sign of a hangover is due to lack of electrolytes.
셋째, 술의 찌꺼기인 아세트 알데히드가 미치는 각종 부작용으로, 괜히 짜증이 나고 속이 메스꺼운 현상 등이 바로 이 증상이다.Third, the various side effects of acetic aldehyde, the dregs of alcohol, are annoying and nauseous.
이와 같은 숙취를 해소하기 위한 음식으로 예로부터 콩나물, 북어, 녹두, 칡, 헛개나무, 구기자 등의 음식이 이용되는 것으로 알려져 있다. It is known that foods such as bean sprouts, bookfish, mung bean, safflower, barn tree, wolfberry, etc. are used as a food for eliminating such hangovers.
칡은 알코올을 분해하는 성분이 강하므로 술독을 분해하는 효과가 크고 생강은 술독을 풀어 주면서 위를 따뜻하게 해 주고 소화를 도와준다. 인삼은 술 마신 다음날 피로를 풀어주고 갈증을 없애며 입맛이 살아나게 해 준다. 구기자는 술로 인해 눈에 피로가 오고 충혈되는 사람에게 좋으며 간의 부담을 덜어주며, 향이 좋아 마시기에도 좋다. 모과 후박은 술독으로 사지가 무거우며 다리가 풀리는 사람의 몸을 가볍게 해 주고 술 마시고 난 후 울렁거리고 답답한 속을 편안하게 해 준다.Because alcohol is a strong component to decompose alcohol has a great effect of decomposing alcohol and ginger to release the poison while warming the stomach and help digestion. Ginseng relieves fatigue, quenches thirst and improves taste the day after drinking. Goji berries are good for people who are tired of eyes and congested by alcohol and relieve the burden on their livers. The quince hubac is a liquor poison that makes the limbs heavy and lightens the person's legs and makes them feel relaxed after drinking.
헛개나무열매는 맛은 달고 먹기 좋으며 숙취해소에 뛰어난 효과가 있다. 술로 인한 지방간, 간염(알코올성간염), 간경화, 황달, 당뇨에 좋으며 갈증을 해소하고 번열을 없애며 대소변을 원활하게 한다. 산수유, 구기자, 오가피를 같이 배합해서 달여도 효과가 좋다. Barberry fruit is sweet and easy to eat and has an excellent effect on relieving hangovers. It is good for fatty liver, hepatitis (alcoholic hepatitis), cirrhosis, jaundice, diabetes caused by alcohol, quenches thirst, eliminates heat, and smooths feces. Cornus, wolfberry, and Ogapi can also be combined and sweetened.
또한, 대한민국 공개특허 제1998-076168호 및 공개특허 제1997-000075호는 녹두를 첨가한 간기능 보호 식품이 개시되어 있고, 제181168호는 오리나무와 마가목 추출물로 이루어진 숙취 해소용 천연차가 개시되어 있다.In addition, Korean Patent Publication Nos. 1998-076168 and 1997-000075 disclose liver-protective foods containing green beans, and No. 181168 discloses a natural tea for hangover resolution consisting of alder and rowan extract. have.
그러나 이와 같은 숙취 해소를 위한 음식 및 발명들의 경우에도 숙취를 효과적으로 해결할 수 있는 조성물의 개발은 아직 미진한 실정이다.However, even in the case of foods and inventions for eliminating hangovers, the development of a composition that can effectively solve the hangover is still insufficient.
본 발명은 상기와 같은 문제점을 해결하기 위하여 안출된 것으로, 알코올 섭취후 혈중 알코올의 분해속도를 증진하고, 항산화 활성 및 염증 억제에 효과가 탁월한 숙취해소용 조성물 및 그 제조방법을 제공하는 것을 그 목적으로 한다.The present invention has been made to solve the above problems, to provide a hangover relief composition and a method for producing a hangover that is excellent in promoting the decomposition rate of alcohol in the blood after alcohol intake, inhibiting antioxidant activity and inflammation. It is done.
본 발명의 다른 목적은 각각의 성분을 적절하게 배합함으로서 각 성분 단독에 비하여 상승적인 숙취해소 효과가 있는 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition having a synergistic hangover effect compared to each component alone by properly blending each component.
본 발명은 상기의 목적을 달성하기 위한 것으로, 헛개나무, 인진쑥, 칡, 대잎둥글레, 배초향, 엉겅퀴 및 감초의 추출물을 포함한 숙취해소용 조성물을 제공한다.The present invention to achieve the above object, provides a hangover composition for the hangover, including the extract of the larvae, Injin mugwort, 칡, jujube round, pear herb, thistle and licorice.
또한, 상기 조성물은 헛개나무 20 ~ 40중량%, 인진쑥 15 ~ 35중량%, 칡 15 ~ 35중량%, 대잎둥글레 5 ~ 25중량%, 배초향 5 ~ 25중량%, 엉겅퀴 5 ~ 25중량% 및 감초 5 ~ 25중량%의 추출물인 것을 특징으로 한다.In addition, the composition is 20 to 40% by weight of larvae, 15 to 35% by weight of jinjinmyeong, 15 to 35% by weight, 5 to 25% by weight of round leaves, pearweed 5 to 25% by weight, thistle 5 to 25% by weight and licorice It is characterized in that the extract of 5 to 25% by weight.
또한, 상기 조성물은 헛개나무 20 ~ 30중량%, 인진쑥 15 ~ 25중량%, 칡 15 ~ 25중량%, 대잎둥글레 5 ~ 10중량%, 배초향 5 ~ 10중량%, 엉겅퀴 5 ~ 10중량% 및 감초 5 ~ 10중량%의 추출물인 것을 특징으로 한다.In addition, the composition is 20 to 30% by weight of larvae, 15 to 25% by weight of jinjin wormwood, 15 to 25% by weight, 5 to 10% by weight of round leaves, vinegar 5 to 10% by weight, thistle 5 to 10% by weight and licorice It is characterized in that the extract of 5 to 10% by weight.
또한, 상기 추출물은 열수 추출물 또는 알코올 추출물인 것을 특징으로 한다.In addition, the extract is characterized in that the hydrothermal extract or alcohol extract.
또한, 상기 조성물은 비타민, 무기질, 락토오스, 덱스트로스, 전분, 수크로스 또는 이들의 혼합물을 더 포함하는 것을 특징으로 한다.In addition, the composition is characterized in that it further comprises vitamins, minerals, lactose, dextrose, starch, sucrose or a mixture thereof.
또한 본 발명은 원료인 헛개나무, 인진쑥, 칡, 대잎둥글레, 배초향, 엉겅퀴 및 감초를 각각 칭량한 후 분쇄하는 단계; 상기 칭량된 원료를 열수 추출 또는 알코올 추출하는 단계; 상기 추출물을 여과 후, 농축하는 단계; 상기 농축물을 포장기에 넣고 충진 후 포장하는 단계를 포함하는 숙취해소용 조성물의 제조방법을 제공한다.In another aspect, the present invention comprises the step of pulverizing after weighing each of the raw material of barley, jinjinmu, 칡, jujube round, pear scent, thistle and licorice; Hydrothermal extraction or alcohol extraction of the weighed raw material; Filtering and then extracting the extract; It provides a method for producing a hangover relief composition comprising the step of filling the concentrate in a packaging machine and then packed.
또한, 상기 농축단계는 추출물 여과 후 50 ~ 60 브릭스(brix)가 될 때까지 교반 및 가열하여 농축하는 것을 특징으로 한다.In addition, the concentration step is characterized in that the concentration by stirring and heating until the
본 발명에 의하면, 알코올 섭취 후 혈중 알코올의 분해속도를 증진하고, 항산화 활성 및 염증 억제 효과가 있는 조성물로서, 각각의 식물들의 추출물을 적절하게 배합함으로서 각각의 성분들을 단독으로 취하는 것에 비하여 상승적인 숙취해소 효과가 있는 숙취해소용 조성물 및 그 제조방법을 제공할 수 있다.According to the present invention, as a composition which enhances the decomposition rate of blood alcohol after ingesting alcohol and has an antioxidant activity and an inhibitory effect, synergistic hangover compared to taking each component alone by appropriately combining extracts of each plant It is possible to provide a composition for releasing hangover and a method for producing the same.
본 발명은 헛개나무, 인진쑥, 칡, 대잎둥글레, 배초향, 엉겅퀴 및 감초의 추출물을 포함한 숙취해소용 조성물에 관한 것이다.The present invention relates to a hangover composition comprising the extract of the bark, Injin mugwort, 칡, jujube round, pear scent, thistle and licorice.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에 따른 조성물은 헛개나무 20 ~ 40 중량%, 인진쑥 15 ~ 35 중량%, 칡 15 ~ 35 중량% 및 대잎둥글래 5 ~ 25 중량%, 배초향 5 ~ 25 중량%, 엉겅퀴 5 ~ 25 중량% 및 감초 5 ~ 25 중량%를 혼합하여 추출한 조성물임에 그 특징이 있다. 더욱 바람직하게는 헛개나무 20 ~ 30%, 인진쑥 15 ~ 25%, 칡 15 ~ 25% 가 함유되며, 대잎둥글레, 배초향, 엉컹퀴 및 감초는 5 ~ 10%의 비율을 가지게 하는 것이 바람직하다. 이때, 본 발명 혼합물의 추출물은 식품공전에 식품재료로 등재되어있는 식물소재로 안전성은 이미 확보되어 있는 소재를 이용하여 적절한 배합 구성비를 가지는 조성물로 숙취 해소에 효과가 탁월한 것을 특징으로 한다. 상기 추출물은 사용되는 용매에 따라 알코올 혹은 열수 추출물일 수 있다. 하기 표 1에 본 발명에 따른 조성물의 구성성분 및 그 배합비율을 나타내었다.The composition according to the present invention is 20 to 40% by weight of larvae, 15 to 35% by weight of jinjin wormwood, 15 to 35% by weight and 5 to 25% by weight of larvae, 5 to 25% by weight of vinegar, 5 to 25% by weight of thistle And licorice is characterized by the composition extracted by mixing 5 to 25% by weight. More preferably, 20 to 30% of larvae, 15 to 25% of jinjin mugwort, and 15 to 25% of larvae are contained, and it is preferable to have a ratio of 5 to 10% of round leaves, pear scents, burdock and licorice. At this time, the extract of the mixture of the present invention is a plant material that is listed as a food material in the food industry, using a material that is already secured safety, characterized in that it has an excellent effect on resolving hangover as a composition having a suitable composition ratio. The extract may be an alcohol or hot water extract depending on the solvent used. Table 1 shows the components of the composition according to the present invention and its blending ratio.
또한 본 발명의 조성물은 상기한 성분 이외에 조성물의 안정성 및 생체조절기구를 활성화시킬 수 있는 비타민류 및 무기질을 첨가할 수 있다. 동시에 본 숙취 조성물은 약학적 혹은 생리학적으로 허용된 담체 즉, 락토스, 덱스트로스, 전분 및 수크로스 등의 성분을 추가할 수 있다.In addition, the composition of the present invention may add vitamins and minerals that can activate the stability and bioregulatory mechanism of the composition in addition to the above components. At the same time, the present hangover composition may add ingredients such as pharmaceutically or physiologically acceptable carriers, such as lactose, dextrose, starch and sucrose.
본 발명에 따른 조성물의 1일 인체 섭취량은 천연 약제를 함유하는 조성물의 경우 10g 내지 35g인 경우가 바람직하나 실제 투여량은 각 개인의 나이, 성별, 체중 및 증상에 따라 결정되어야 하며, 이 농도는 본 발명의 범위를 한정하지는 않는다. 본 발명의 숙취해소 조성물의 독성 검사를 ICR 마우스를 이용하여 경구투여한 결과 6.7g/Kg 이상에서 50%의 치사량(LD50) 값을 보인 바, 본 조성물은 생체에 매우 안전한 것을 확인하였다.The daily human intake of the composition according to the present invention is preferably 10g to 35g for a composition containing a natural medicine, but the actual dosage should be determined according to the age, sex, weight and symptoms of each individual, It does not limit the scope of the invention. Toxicity test of the hangover relief composition of the present invention by oral administration using ICR mice showed a 50% lethal dose (LD50) value of 6.7g / Kg or more, it was confirmed that the composition is very safe for the living body.
이하 본 발명의 제조방법을 단계별로 상세히 설명한다.Hereinafter, the manufacturing method of the present invention will be described in detail step by step.
1) 원료 칭량 및 분쇄단계1) Raw material weighing and grinding step
각 구성 식물을 칭량 후 믹서를 이용하여 혼합된 구성물을 분쇄한다.After weighing each component, the blended composition is ground using a mixer.
2) 추출단계2) Extraction step
상기 분쇄된 원료를 열수 또는 알코올로 추출할 수 있다. 예를 들어, 칭량된 중량의 10배되는 증류수를 첨가하여 100 ~ 140℃에서 3 ~ 6시간 교반하며 가열할 수 있다.The ground raw material may be extracted with hot water or alcohol. For example, distilled water 10 times the weighed weight may be added and heated with stirring at 100-140 ° C. for 3-6 hours.
3) 여과 및 농축단계3) Filtration and concentration step
여과포를 이용하여 조성성분의 추출물을 여과한 후, 50 ~ 60 브릭스(brix)가 될 때까지 교반 및 가열을 통하여 농축한다.After filtering the extract of the composition using the filter cloth, it is concentrated by stirring and heating until 50 to 60 brix (brix).
4) 포장단계4) Packing step
상기 발명된 추출물을 포장기에 넣어 농축액을 차의 원료로 사용할 수 있고, 액상차로 판매하는 경우에는 적절하게 희석하여 포장토록 한다.Put the extract of the invention in a packaging machine can be used as a raw material of the tea concentrate, if sold as a liquid tea to be properly diluted and packaged.
5) 섭취방법5) Intake Method
상기 본 발명 조성물은 개인별로 적절한 양을 섭취하며, 보통 1일 2 ~ 6 브릭스(brix)의 추출액 80 ~ 120ml을 음주 전 혹은 후에 섭취할 수 있다.The composition of the present invention ingests the appropriate amount for each individual, usually can be ingested before or after drinking 80 ~ 120ml of 2 ~ 6 Brix (brix) extract per day.
이하 본 발명인 숙취해소 조성물의 기능에 대한 확인을 위해 이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples to confirm the function of the hangover relief composition of the present invention. These examples are only for illustrating the present invention in more detail, it will be apparent to those skilled in the art that the scope of the present invention is not limited to these embodiments.
실시예Example
본 발명에 따른 조성물의 제조Preparation of the composition according to the invention
헛개나무, 인진쑥, 칡, 대잎둥글레, 배초향, 엉겅퀴 및 감초 등의 한방 재료를 엄선한 후 세척하여 이물을 제거하였다. 원료대비 5 ~ 10배 가량의 정제수를 가하여 105℃이상의 조건에서 5시간 이상 추출하였다. 추출액을 여과한 후 진공 농축기를 이용하여 50 ~ 60 브릭스(brix)까지 농축하였다. 농축이 완료된 제품을 90℃에서 15 ~ 20분 동안 살균한 후 실험 재료로 사용하였다.Herbal ingredients such as bark tree, Injin mugwort, 칡, round leaf, pear scent, thistle and licorice were carefully selected and washed to remove foreign substances. 5 to 10 times more purified water was added and extracted for more than 5 hours under the condition of 105 ℃ or more. The extract was filtered and concentrated to 50 to 60 brix using a vacuum concentrator. The concentrated product was sterilized for 15 to 20 minutes at 90 ℃ was used as an experimental material.
실험예 1Experimental Example 1
급성 알코올 분해능 측정Acute Alcohol Resolution Measurement
식이에 의한 알코올 흡수와 분해의 차이를 없애기 위해서 마우스를 5시간 절식시키고, 각 군당 5마리의 마우스에 본 발명인 숙취해소 조성물의 원액, 4배 희석액 및 16배 희석액을 각각 마우스 체중 Kg 당 10ml을 경구투여하였다. 투여 1시간 후 마우스 체중 Kg당 12.5ml의 알코올(99.9%)을 경구투여하였다. 알코올 투여 1시간 후에 마우스 꼬리로부터 체혈 후, 혈청을 회수(3000 X g /10분)하였다. 혈청 알코올 농도측정은 퀀티크롬 에탄올(Quantichrom Ethanol) 측정 키트(kit)(Roche, Hayward, CA) 이용하여 540nm의 흡광도를 측정후, 키트 내의 표준 알코올 시료를 분석하여 얻은 표준곡선에 실험 결과를 대입하여 알코올의 함량을 측정하였다. 실험 결과 50brix의 원액을 4배 희석한 희석액에서 가장 우수한 알코올 분해력을 보였다(도 1). In order to eliminate the difference in alcohol absorption and degradation due to diet, mice were fasted for 5 hours, and 5 mice of each group were orally treated with the stock solution, 4-fold dilution, and 16-fold dilution of the hangover relief composition of the present invention, respectively. Administered. One hour after administration, 12.5 ml of alcohol (99.9%) per Kg of mouse body was administered orally. After 1 hour of alcohol administration, after bleeding from the tail of the mouse, the serum was recovered (3000 X g / 10 minutes). Serum alcohol concentration was measured by measuring the absorbance at 540 nm using a Quantichrom Ethanol measurement kit (Roche, Hayward, CA), and substituting the experimental results into a standard curve obtained by analyzing standard alcohol samples in the kit. The content of alcohol was measured. Experimental results showed the best alcohol degrading power in diluting solution diluted 4 times the stock of 50brix (Fig. 1).
이상의 결과를 바탕으로 알코올 투여 후 시간별로 알코올 분해능을 측정하였다. 실험 결과 4배 희석된 본 발명 조성물은 알코올만 섭취한 마우스와 비교하여 유의하게 혈중 알코올 함량이 낮아진 결과를 보였다(도 2).Based on the above results, alcohol resolution was measured by time after alcohol administration. Experimental results 4-fold dilution of the composition of the present invention showed a significantly lower blood alcohol content compared to the mice ingested only alcohol (Fig. 2).
실험예 2Experimental Example 2
알코올 섭취에 의한 위출혈 억제효과Gastric Hemorrhage Inhibitory Effect by Alcohol Intake
실험예 1 및 2와 동일한 조건으로 알코올을 마우스에 투여 후, 마우스를 경추탈골법으로 희생시킨 후, 복부를 절개하여 위 조직을 적출하였다. 상기 적출한 위 조직은 3% 포르말린을 이용하여 조직을 고정 후, 위 손상 정도를 관찰하고 육안관찰 소견을 정리하였다. 그 결과 본 발명인 숙취 해소 조성물을 섭취한 경우에 위점막 출혈 현상이 억제된 결과를 보였고(도 3), 표 2에 나타낸 바와 같이 본 발명 조성물을 섭취한 경우가 위점막 손상정도가 가장 낮은 결과를 보였다.After the alcohol was administered to the mice under the same conditions as in Experimental Examples 1 and 2, the mice were sacrificed by cervical distal bone method, and the stomach was excised to remove the stomach tissue. The extracted gastric tissue was fixed with tissue using 3% formalin, and then the degree of gastric injury was observed and visual observations were arranged. As a result, the gastric mucosa bleeding phenomenon was suppressed when the present inventors consumed the hangover relief composition (FIG. 3), and as shown in Table 2, the gastric mucosal injuries resulted in the lowest result. Seemed.
실험예 3Experimental Example 3
복강세포로부터 염증성 성분의 생산 억제에 미치는 효과 Effect on Inhibition of Inflammatory Components from Peritoneal Cells
염증은 자극물질에 의한 혈관의 팽창에 의하여 유도된다. 이러한 염증의 유발은 여러 가지 염증성 싸이토카인의 영양을 받기에, 본 실험예에서는 마우스의 대식세포로부터 생산되는 염증성 싸이토카인 및 염증유발 물질인 질소산화물(nitric oxide; NO)의 생산에서 본 발명 조성물의 효과에 대하여 검증하였다. 마우스의 복강세포(peritoneal exudative cells; PEC)로부터 대식세포의 수집은 6주령의 Balb/c 마우스의 복강에 티오글리콜래이트(thioglycollate)를 주사하여 세포를 회수한 후, 세포배양 프레이트에 부착되는 세포를 대식세포로 이용하였다. 대식세포에 염증유도 물질로서 LPS(lipopolysaccharide)를 최종농도가 0.5㎍/mL이 되도록 조정하여 첨가함으로 염증성 싸이토카인을 생산하게 하였다. 본 발명 조성물의 염증성 싸이토카인의 생산 억제효과를 측정하여 위하여 LPS 처리 직후에 16배 희석액으로부터 256배의 본 발명 조성물을 첨가하고 24시간 동시 배양하였다. 배양 완료 후 원심분리를 통하여 배양 상등액을 수집하였으며, 배양 상등액에 유도된 TNF-α, IL-6등의 염증성 싸이토카인의 양은 각 엘리사 키트(ELISA kit)(Pharmingen, CA, USA)를 이용하여 제조사의 지침에 따라 측정하였다. 실험결과 본 발명 조성물은 LPS에 의하여 생산되는 염증성 싸이토카인의 생산을 억제하는 효과가 있었다.(도 4)Inflammation is induced by the expansion of blood vessels by irritants. Since the induction of inflammation is nourishment of various inflammatory cytokines, in this experimental example, the effects of the composition of the present invention on the production of inflammatory cytokines and nitric oxides (NO), which are produced from macrophages in mice, are produced. It was verified. Macrophage collection from peritoneal exudative cells (PECs) of mice was performed by injecting thioglycollate into the abdominal cavity of 6-week-old Balb / c mice to recover the cells, and then attach them to the cell culture plate. Was used as macrophages. Inflammatory cytokines were produced by adding LPS (lipopolysaccharide) as a inflammatory inducer to macrophages so that the final concentration was adjusted to 0.5 μg / mL. In order to measure the inhibitory effect of the inflammatory cytokine production of the composition of the present invention, immediately after LPS treatment, 256-fold of the present composition was added from a 16-fold dilution and co-cultured for 24 hours. After completion of the culture, the culture supernatant was collected by centrifugation, and the amount of inflammatory cytokines such as TNF-α and IL-6 induced in the culture supernatant was determined using the manufacturer's ELISA kit (Pharmingen, CA, USA). Measurement was made according to the instructions. Experimental results The composition of the present invention had the effect of inhibiting the production of inflammatory cytokines produced by LPS.
일산화 질소(NO, nitric oxide) 함량은 안정된 NO 산화물인 NO2(nitrite)를 Griess 반응을 이용하여 측정하였다. 즉, 대식세포를 염증유도 물질인 LPS와 본 발명조성물을 첨가하고 24시간 배양 후에 배양상등액에 생산된 NO의 양을 측정하였다. NO 양의 측정은 대식세포 배양 상등액 0.1 ml을 96 웰 플래이트(well plate)에 넣고 여기에 Griess 시약(0.1% N-1-나프틸-에틸렌디아민/H2O (N-1-naphthyl-ethylendiamine/H2O) : 1% 술파닐아마이드(sulfanilamide)/5% H3PO4=1:1)을 동량 첨가하여 10분간 반응시킨 후, 마이크로플레이트 리더(microplate reader)로 570nm에서 흡광도를 측정하였다. 나이트라이트(Nitrite)의 농도는 소듐 나이트라이트(sodium nitrite)를 이용하여 얻은 표준곡선과 비교하여 표현하였다. 실험결과 본 발명 조성물은 LPS에 의하여 유도되는 산화질소(nitric oxide)의 생산을 유의적으로 억제함으로써 항염증 및 항산화 작용에 탁월한 효과가 입증 되었다(도 5).Nitric oxide (NO) content was measured using the Griess reaction, a stable NO oxide NO 2 (nitrite). That is, the amount of NO produced in the culture supernatant was measured after 24 hours of incubation with the addition of LPS, an inflammation-inducing substance, and the present invention. Determination of the NO amount was carried out by placing 0.1 ml of macrophage culture supernatant into a 96 well plate and adding Griess reagent (0.1% N-1-naphthyl-ethylenediamine / H 2 O (N-1-naphthyl-ethylendiamine / H 2 O): 1% sulfanilamide / 5% H 3 PO 4 = 1: 1) was added in the same amount, and reacted for 10 minutes, and the absorbance was measured at 570 nm with a microplate reader. The concentration of nitrite was expressed by comparison with a standard curve obtained using sodium nitrite. Experimental results showed that the composition of the present invention significantly inhibits the production of nitric oxide induced by LPS, and thus has an excellent effect on anti-inflammatory and antioxidant activity (FIG. 5).
실험예 4Experimental Example 4
모세혈관 투과 억제도Capillary Permeation Inhibition
본 발명 조성물에 의한 혈액의 모세혈관 투과 억제도 실험은 휘틀(Whittle) 방법을 변형하여 측정하였다(Whittle, 1964). 즉, ICR계 마우스에 본 발명 조성물을 복강내 주사(체중 Kg당 50㎎ 또는 200㎎)하고 30분 후에 생리 식염수에 희석된 0.7% 아세트산(acetic acid)을 제조하여 체중 Kg당 10 ㎖을 복강내 주사하였다. 30분 후 생리식염수에 녹여 제조한 4% 폰타민 스카이 블루(pontamine sky blue)를 0.1㎖ 용량으로 꼬리정맥에 정맥주사하고, 30분 후 경추 탈골법으로 실험동물을 폐사시켰다. 그 후 복강내로 5㎖의 생리식염수를 복강에 가하고 복부를 가볍게 흔들어준 후, 혈관으로부터 투과하여 복강에 삼출된 폰타민 스카이 블루(pontamine sky blue)를 취하였다. 복강에 삼출된 폰타민 스카이 블루의 양은 자외선/가시광선 분광광도계(UV/visible spectrophotometer)를 사용하여 590㎚에서 흡광도를 측정하여 대조군과 비교하였다. 실험 결과 본 발명 조성물은 아세트산에 의한 혈관의 확장을 억제함으로서 장관막에 유출되는 혈액성분의 투과를 유의하게 억제하는 것이 확인되었다(도 6).Inhibition of capillary permeation of blood by the composition of the present invention was measured by modifying the Whittle method (Whittle, 1964). In other words, ICR mice were intraperitoneally injected with the present composition (50 mg or 200 mg per kg body weight) and after 30 minutes, 0.7% acetic acid (acetic acid) diluted in physiological saline was prepared to intraperitoneally 10 ml per kg body weight. Injection. After 30 minutes, 4% pontamine sky blue prepared by dissolving in physiological saline was injected intravenously into the tail vein at a dose of 0.1 ml, and after 30 minutes, the animals were killed by cervical dislocation. Thereafter, 5 ml of physiological saline was added to the abdominal cavity and the abdomen was gently shaken. Then, pontamine sky blue penetrated from the blood vessel and exuded into the abdominal cavity was taken. The amount of pontamin sky blue exuded into the abdominal cavity was compared with the control group by measuring the absorbance at 590 nm using an ultraviolet / visible spectrophotometer. As a result of the experiment, the composition of the present invention was found to significantly inhibit the permeation of blood components flowing into the intestinal membrane by inhibiting the expansion of blood vessels by acetic acid (FIG. 6).
실험예 5Experimental Example 5
알코올을 투여한 마우스에서 본 발명 조성물을 구성하는 각각의 성분의 투여와 본 발명 조성물의 투여에 의한 혈중 알코올 함량 비교Comparison of blood alcohol content by administration of each component constituting the composition of the present invention and administration of the composition of the present invention in mice administered alcohol
본 발명에 따른 조성물을 구성하는 각각의 성분의 알코올 분해효과를 실험예 1의 방법에 준하여 실험하였다. 즉, 본 발명 조성물 12.5 브릭스에 포함되는 각각의 성분의 함량을 본 발명 조성물의 제조방법과 동일하게 제조한 후, 동일한 양(Kg 당 10 ml)을 경구투여하고, 투여 1시간 후 마우스 체중 Kg당 12.5 ml의 알코올(99.9%)을 경구투여하였다. 알코올 투여 1시간 후에 마우스 혈액으로부터 혈청을 회수하여 알코올 농도를 측정하였다. 실험 결과 본 발명조성물은 조성물을 구성하는 각각의 성분에 비하여 낮은 알코올 함량이 측정된 바, 본 발명 조성물을 체내에서 알코올 대사를 각각의 구성성분에 비하여 높이는 상승작용을 유도한다는 것을 확인하였다(표 3).The alcohol decomposition effect of each component constituting the composition according to the present invention was tested according to the method of Experimental Example 1. That is, after preparing the content of each component contained in the composition 12.5 brix of the present invention in the same manner as the preparation method of the composition of the present invention, the same amount (10 ml per Kg) orally administered, 1 hour after the administration of the body weight of Kg 12.5 ml of alcohol (99.9%) was administered orally. Serum was collected from mouse blood 1 hour after alcohol administration, and alcohol concentration was measured. As a result of the experiment, the composition of the present invention was found to have a low alcohol content compared to the respective components constituting the composition, and it was confirmed that the composition of the present invention induces synergism to increase alcohol metabolism in comparison with the respective components (Table 3). ).
조성물The present invention
Composition
함량(%)Alcohol
content(%)
둥글래Leaves
Round
함량(%)Alcohol
content(%)
도 1은 최적의 알코올 분해능을 가지는 본 발명에 따른 조성물의 희석비를 나타낸 그래프.1 is a graph showing the dilution ratio of a composition according to the present invention having an optimal alcohol resolution.
도 2는 알코올 투여 후 본 발명 조성물에 의한 혈중 알코올 함량 변화를 나타낸 그래프.Figure 2 is a graph showing the blood alcohol content change by the composition of the present invention after alcohol administration.
도 3은 알코올 처리에 의한 위 염증 억제 효과를 보이기 위한 조직의 사진.Figure 3 is a photograph of a tissue for showing the gastric inflammation inhibitory effect by alcohol treatment.
도 4는 본 발명 조성물에 의한 대식세포로부터 염증성 싸이토카인의 생산 억제효과를 나타낸 그래프.Figure 4 is a graph showing the inhibitory effect of the production of inflammatory cytokines from macrophages by the composition of the present invention.
도 5는 본 발명 조성물에 의한 대식세포로부터 산화질소물(NO)의 생산 억제효과를 나타낸 그래프.Figure 5 is a graph showing the effect of inhibiting the production of nitric oxide (NO) from macrophages by the composition of the present invention.
도 6은 초산에 모세혈관 투과도 억제 실험 결과를 나타낸 그래프.6 is a graph showing the results of capillary permeability inhibition experiment in acetic acid.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090091211A KR20110033644A (en) | 2009-09-25 | 2009-09-25 | Composition for curing hangover and method manufacturing thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090091211A KR20110033644A (en) | 2009-09-25 | 2009-09-25 | Composition for curing hangover and method manufacturing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110033644A true KR20110033644A (en) | 2011-03-31 |
Family
ID=43938020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090091211A KR20110033644A (en) | 2009-09-25 | 2009-09-25 | Composition for curing hangover and method manufacturing thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20110033644A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101368460B1 (en) * | 2012-03-19 | 2014-03-12 | 신영수 | Composition for curing a hangover and it's making method |
| KR101461165B1 (en) * | 2012-04-19 | 2014-11-13 | 권재윤 | Hangover curing agent |
| KR20170015842A (en) | 2015-07-31 | 2017-02-09 | 재단법인 전남생물산업진흥원 | Composition for treating hangover comprising extracts of fruits of stauntonia hexaphylla |
| KR20170015844A (en) | 2015-07-31 | 2017-02-09 | 재단법인 전남생물산업진흥원 | Hepatoprotective composition comprising extracts of fruits of stauntonia hexaphylla for preventing alcoholic liver injury |
| KR20170085451A (en) * | 2016-01-14 | 2017-07-24 | 주식회사 프라임오라 | Composition for eliminating hangover |
| KR20180059588A (en) * | 2016-11-25 | 2018-06-05 | 뉴트라팜주식회사 | Food composition comprising pine tree bark extract for improving liver function and relieving hangover |
| KR101982816B1 (en) | 2018-08-23 | 2019-05-29 | 주식회사 비앤에이치랩 | Composition for removing hangover and improving liver function containing Saltwort |
| KR20210072320A (en) | 2019-12-09 | 2021-06-17 | 조성덕 | Method for manufacturing hangover-relieving beverages using fruit of barn tree and pueraria lobata |
| KR20220085638A (en) * | 2020-12-15 | 2022-06-22 | (주)옵티마케어 | Liquid tea composition having a hangover relief effect and its manufacturing method |
-
2009
- 2009-09-25 KR KR1020090091211A patent/KR20110033644A/en not_active Application Discontinuation
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101368460B1 (en) * | 2012-03-19 | 2014-03-12 | 신영수 | Composition for curing a hangover and it's making method |
| KR101461165B1 (en) * | 2012-04-19 | 2014-11-13 | 권재윤 | Hangover curing agent |
| KR20170015842A (en) | 2015-07-31 | 2017-02-09 | 재단법인 전남생물산업진흥원 | Composition for treating hangover comprising extracts of fruits of stauntonia hexaphylla |
| KR20170015844A (en) | 2015-07-31 | 2017-02-09 | 재단법인 전남생물산업진흥원 | Hepatoprotective composition comprising extracts of fruits of stauntonia hexaphylla for preventing alcoholic liver injury |
| KR20170021272A (en) | 2015-07-31 | 2017-02-27 | 재단법인 전남생물산업진흥원 | Composition for treating hangover comprising extracts of fruits of stauntonia hexaphylla |
| KR20190037219A (en) | 2015-07-31 | 2019-04-05 | 재단법인 전남생물산업진흥원 | Composition for treating hangover comprising extracts of fruits of stauntonia hexaphylla |
| KR20170085451A (en) * | 2016-01-14 | 2017-07-24 | 주식회사 프라임오라 | Composition for eliminating hangover |
| KR20180059588A (en) * | 2016-11-25 | 2018-06-05 | 뉴트라팜주식회사 | Food composition comprising pine tree bark extract for improving liver function and relieving hangover |
| KR101982816B1 (en) | 2018-08-23 | 2019-05-29 | 주식회사 비앤에이치랩 | Composition for removing hangover and improving liver function containing Saltwort |
| KR20210072320A (en) | 2019-12-09 | 2021-06-17 | 조성덕 | Method for manufacturing hangover-relieving beverages using fruit of barn tree and pueraria lobata |
| KR20220085638A (en) * | 2020-12-15 | 2022-06-22 | (주)옵티마케어 | Liquid tea composition having a hangover relief effect and its manufacturing method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20110033644A (en) | Composition for curing hangover and method manufacturing thereof | |
| KR20120084723A (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition, preparative method and usage thereof | |
| KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
| KR20020041639A (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
| KR101281988B1 (en) | Composition having eleutherococcus senticosus for treating hangover and improving liver function, and the preparation method thereof | |
| CN110960638A (en) | Composition for reducing uric acid and preparation method thereof | |
| CN105166544A (en) | Pig mixed feed and preparation method thereof | |
| KR100649128B1 (en) | Manufacturing method of functional food composition including maesil | |
| KR101461165B1 (en) | Hangover curing agent | |
| KR101217080B1 (en) | Composition having herb extract as active incredient for treating hangover and preparation method thereof | |
| CN103007111B (en) | Chinese medicinal preparation for treating diarrhea of rabbits and preparation method of Chinese medicinal preparation | |
| KR100638491B1 (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
| KR100500373B1 (en) | Composition for hangover cures | |
| KR101113603B1 (en) | Extract composition of herbal mixture for improving liver fucntion and relieving hangover | |
| KR20020078467A (en) | Drink for tonic liver and Manufacture process the same. | |
| KR102136053B1 (en) | Composition for Removing Hangover Comprising Herb Extract and Beverage Thereof | |
| KR20030021667A (en) | Beverage composition for treating hangover | |
| KR20070047396A (en) | A functional beverage using hericium erinaceus extracts and manufacturing process of the same | |
| KR101391647B1 (en) | Anti obesity composition | |
| KR102588372B1 (en) | Composition comprising natural complex extract for prenenting, improving or treating gastritis and peptic ulcer | |
| CN116747286B (en) | A Chinese medicinal composition with weight reducing effect, and its preparation method | |
| KR102470454B1 (en) | Health functional food composition for anti-obesity comprising gynostemma pentaphyllum leaf extract and complex extract, and manufacturing method thereof | |
| KR100877507B1 (en) | Composition for treating hangover comprising extracts of persimmon leaves as a main component | |
| KR20030079289A (en) | The carbonated soft drinks a manufacturing process and a composition of ling indigestion hangover cures. | |
| CN107875222A (en) | A kind of Chinese medicine preparation for preventing and treating lamb dysentery and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |